The Vaccine and Infectious Disease Division’s (VIDD) strategy involves methodically uncovering findings in the laboratory that inform prevention studies in the clinic. Advanced statistical methods are used to analyze our experiments and reveal practical insights that guide patient care. Our advanced computational analyses help scientists and policymakers predict and prevent future outbreaks.
Our research encompasses an international scope, seeking preventions and cures for globally significant diseases including COVID-19, HIV, Ebola, tuberculosis, malaria and West Nile Virus. We also maintain robust research efforts to prevent and treat the most dangerous infections for cancer patients and people with weakened immune systems. These include cytomegalovirus, respiratory syncytial virus and multiple herpes viruses.
Using mathematical modeling, computational biology, epidemiology and statistics, scientists within our Biostatistics, Bioinformatics and Epidemiology (BBE) Program determine how infectious diseases are spread and contained. Our researchers collaborate across multiple research areas to incorporate biostatistics, bioinformatics and population modeling throughout vaccine design, development, evaluation and deployment.
The Bedford Lab studies the dynamics of virus populations to understand how strains evolve and spread throughout the world, with particularly interest in how viruses mutate in response to immune responses.
The Fong Group uses biostatistical modeling and computational methods to analyze the effectiveness of vaccine candidates in HIV, dengue and cholera clinical trials.
The Gilbert Group is focused on the statistical design and analysis of HIV vaccine efficacy trials, with emphasis on assessing immune correlates of vaccine-induced protection.
The Halloran Group researches study designs and analytic methods for evaluating vaccines in populations. Research includes developing new methods as well as applying existing methods to novel applications.
The Huang Group develops statistical methods for design and analysis of biomarker studies for disease screening, surrogate endpoint identification and treatment selection in cancer and infectious diseases.
Scientists in our Immunology and Vaccine Development (IVD) Program aim to gain a fundamental understanding of the immune system, so we can create effective vaccines against serious global diseases. Our ultimate goal is to create vaccines that induce broader, more effective responses against infectious diseases. We also work to develop novel therapies for cancer, COVID-19, HIV, tuberculosis, malaria and other related infections. Researchers in IVD pursue investigations in the molecular underpinnings of immune regulation, vaccine immune monitoring and HIV vaccine and adjuvant design.
Scientists in our Infectious Disease Sciences (IDS) Program apply laboratory, clinical and computational approaches to advance our knowledge and understanding of infectious diseases such as COVID-19, HIV, HSV-2, West Nile virus, Zika virus. We concentrate on detecting, preventing and treating infectious diseases as well as mitigating serious diseases, including Graft-versus-Host Disease and Cytomegalovirus in immunocompromised individuals, who are at high risk for infection. Our goal is to advance knowledge of host-pathogen interactions and develop innovative management strategies for infectious diseases.
The Boeckh Lab strives to prevent infectious disease in healthy and immunocompromised hosts and to reduce the severity of infections that do occur. The team focuses on COVID-19, herpes viruses, respiratory viruses, and biomarkers that define susceptibility to infectious diseases.
The Corey Lab seeks to understand how tissue resident cells in the genital tract contribute to host containment of HSV-2, with the goal to develop therapies that control HSV-2 reactivation and reduce transmission.
The Fredricks Lab uses molecular biological tools to describe microbial diversity. They identify specific microbial communities associated with disease states including graft-vs.-host disease and bacterial vaginosis.
The Goo Lab researches the immune response to mosquito-borne flaviviruses such as dengue virus, West Nile virus, and Zika virus. By combining tools in virology, molecular biology, immunology, genomics, and epidemiology, the team strives to inform the design of vaccines and antiviral drugs.
The Hill Group studies the epidemiology of infections in immunocompromised populations, with a focus on human herpesvirus 6 (HHV-6) and other viral infections in bone marrow transplant recipients, as well as the infectious complications of CAR-T cell immunotherapies.
The Jerome Lab investigates the use of gene editing enzymes and other gene therapy approaches to target persistent viral infections. These approaches offer the prospect of cure for human immunodeficiency virus, hepatitis B virus, and herpes simplex virus infections.
The Liu Group focuses on evaluating and optimizing the usage of antimicrobials and infectious disease diagnostic tests with the aim to improve outcomes for cancer patients and prevent the emergence and spread of antimicrobial resistant pathogens.
The Menon Group strives to enhance cancer diagnostics in Uganda, and to improve the care of patients with cancer in resource-limited regions.
The Pergam Group studies the prevention of infections in cancer patients, transplant recipients and other immunocompromised populations. They investigate risk factors for healthcare and community-acquired infections in these groups.
The Phipps Group focuses on human herpesvirus-8 virology and the pathogenesis of Kaposi sarcoma (KS). Specific areas of investigation include factors associated with KS presentation and treatment outcomes, as well as host and viral gene expression in KS tumors.
The Schiffer Group uses mathematical models to generate novel hypotheses that inform the design and implementation of clinical and laboratory experiments for the human microbiome and viral infections in persons undergoing stem cell transplantation.
The Wald Lab studies the epidemiology and natural history of chronic viral infections in immunocompetent and immunocompromised hosts leading to the development of clinical trials of antiviral therapeutics and prophylactic and therapeutic vaccines for viral pathogens.